智通财经APP讯，药明巨诺-B(02126)发布截至2025年12月31日止年度业绩，该集团期内取得收入2.84亿元人民币，同比增加79.3%;年内亏损5.55亿元，同比收窄5.98%;每股基本亏损1.34元。
该收入主要来自(i)集团目前处于商业化的产品倍诺达®的销售;及(ii)向Juno授予JW sLVV生产工艺及相关技术知识(以及专利)的非独家许可。产品收入由截至2024年12月31日止年度的人民币1.58亿元增加38.4%至截至2025年12月31日止年度的人民币2.19亿元。截至2025年12月31日止年度确认非独家许可收入人民币 6450万元，为报告期间的整体收入增长作出贡献。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.